Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage

Journal of Child Neurology

Volumn 23, Issue 7, 2008, Pages 748-751

  Rosales, Xiomara Q ^a   Chu Mary Lynn, M L ^b   Shilling, Christopher ^a   Wall, Cheryl ^a   Pastores, Gregory M ^b   Mendell, Jerry R ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Liver disease; Muscular dystrophy; Myopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA SARCOGLYCAN; CORTICOSTEROID; CREATINE KINASE; DEFLAZACORT; DYSTROPHIN; GAMMA GLUTAMYLTRANSFERASE;

ADOLESCENT; ARTICLE; BECKER MUSCULAR DYSTROPHY; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DUCHENNE MUSCULAR DYSTROPHY; GAIT DISORDER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; LIVER BIOPSY; LIVER INJURY; LIVER TOXICITY; MALE; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE FATIGUE; MUSCLE HYPERTROPHY; MUSCLE WEAKNESS; MYOPATHY; PRIORITY JOURNAL; WALKING DIFFICULTY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; LIVER DISEASES; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; REFERENCE VALUES;

EID: 47349098770     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808314365     Document Type: Article

References (32)

1. Pearce JM, Pennington RJ, Walton JN Serum enzyme studies in muscle disease. II. Serum creatine kinase activity in muscular dystrophy and in other myopathic and neuropathic disorders. J Neurol Neurosurg Psychiatry. 1964; 27: 96-99.
2. Somer H., Donner M., Murros J., Konttinen A. A serum isozyme study in muscular dystrophy. Particular reference to creatine kinase, aspartate aminotransferase, and lactic acid dehydrogenase isozymes. Arch Neurol. 1973; 29: 343-345.
3. Rutledge J., Andersen J., Fink CW, et al. Persistent hypertransaminasemia as the presenting finding of childhood muscle disease. Clin Pediatr. 1985; 24: 500-503.
4. Cao A., De Virgiliis S., Lippi C., Coppa G. Serum and muscle creatine kinase isoenzymes and serum aspartate aminotransferase isoenzymes in progressive muscular dystrophy. Enzyme. 1971; 12: 49-62.
5. Lin YC, Lee WT, Huang SF, et al. Persistent hypertransaminasemia as the presenting findings of muscular dystrophy in childhood. Acta Paediatr Taiwan. 1999; 40: 424-429.
6. Begum T., Oliver MR, Kornberg AJ, Dennett X. Elevated aminotransferase as a presenting finding in a patient with occult muscle disease. J Paediatr Child Health. 2000; 36: 189-190.
7. Korones DN, Brown MR, Palis J. "Liver function tests" are not always tests of liver function. Am J Hematol. 2001; 66: 46-48.
8. Urganci N., Arapoglu M., Serdaroglu P., Nuhoglu A. Incidental raised transaminases: A clue to muscle disease. Ann Trop Paediatr. 2006; 26: 345-348.
9. Zatz M., Rapaport D., Vainzof M., et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J Neurol Sci. 1991; 102: 190-196.
10. Abraham S., Begum S., Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004; 63: 123-129.
11. Walker NJ, Zurier RB Liver abnormalities in rheumatic diseases. Clin Liver Dis. 2002; 6: 933-946.
12. Miller EB, Shichmanter R., Friedman JA, Sokolowski N. Granulomatous hepatitis and Sjogren's syndrome: An association. Semin Arthritis Rheum. 2006; 36: 153-158.
13. Akesson A., Berglund K., Karlsson M. Liver function in some common rheumatic disorders. Scand J Rheumatol. 1980; 9: 81-88.
14. Rain F., Durieu I., Mackiewitz R., Levrat R. Dermatopolymyositis and primary biliary cirrhosis. A rare association. Presse Med. 1996; 25: 581-582.
15. Ytterberg SR Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006; 8: 167-173.
16. Kim P., Grossman JM Treatment of mixed connective tissue disease. Rheum Dis Clin North Am. 2005; 31: 549-565.
17. Kissel JT, Levy RJ, Mendell JR, Griggs RC Azathioprine toxicity in neuromuscular disease. Neurology. 1986; 36: 35-39.
18. White MG, Stoward PJ, Christie KN, Anderson JM Proteases in normal and diseased human skeletal muscle: A preliminary histochemical survey. Histochem J. 1985; 17: 819-832.
19. Mokri B., Engel AG Duchenne dystrophy: Electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology. 1975; 25: 1111-1120.
20. McCarter GC, Steinhardt RA Increased activity of calcium leak channels caused by proteolysis near sarcolemmal ruptures. J Membr Biol. 2000; 176: 169-174.
21. Matsumoto T., Yoshimine T., Shimouchi K., et al. The liver in systemic lupus erythematosus: Pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum Pathol. 1992; 23: 1151-1158.
22. Farrell GC Drugs and steatohepatitis. Semin Liver Dis. 2002; 22: 185-194.
23. Stravitz RT, Sanyal AJ Drug-induced steatohepatitis. Clin Liver Dis. 2003; 7: 435-451.
24. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989; 320: 1592-1597.
25. Moxley RT 3rd, Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005; 64: 13-20.
26. Moore SA, Shilling CJ, Westra S., et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol. 2006; 65: 995-1003.
27. Domenico B., Ruzza G., Bonometto P., et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000; 23: 1344-1347.
28. Kohli R., Harris DC, Whitington PF Relative elevations of serum alanine and aspartate aminotransferase in muscular dystrophy. J Pediatr Gastroenterol Nutr. 2005; 41: 121-124.
29. Cepelak I., Zanic Grubisic T., Mandusic A., et al. Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children. Clin Chim Acta. 1998; 276: 121-127.
30. Harasymiw JW, Vinson DC, Bean P. The early detection of alcohol consumption (EDAC) score in the identification of heavy and at-risk drinkers from routine blood tests. J Addict Dis. 2000; 19: 43-59.
31. Peng WK, Sheikh Z., Paterson-Brown S., Nixon SJ Role of liver function tests in predicting common bile duct stones in acute calculous cholecystitis. Br J Surg. 2005; 92: 1241-1247.
32. Rezzani R. Cyclosporine A and adverse effects on organs: Histochemical dies. Prog Histochem Cytochem. 2004; 39: 85-128.